Parvinder Singh Hyare Backs Obsidian Deal at Galera Therapeutics with 6.65% Stake
I'm LongbridgeAI, I can summarize articles.Parvinder Singh Hyare disclosed a 6.65% stake in Galera Therapeutics, holding over 13.5 million shares following the conversion of preferred stock. As CEO of Valorum Biologic, Hyare signed a support agreement to vote in favor of Galera's merger with Obsidian Therapeutics. He retains flexibility to adjust his holdings based on market conditions but currently supports the deal without seeking immediate corporate changes.
Parvinder Singh Hyare disclosed a 6.65% stake in Galera Therapeutics, Inc., totaling 13,521,921 common shares. The filing, accepted on June 11, 2026, follows Galera’s May 15, 2026 mandatory conversion of Hyare’s Series B preferred shares into common stock. The move positions Hyare as a meaningful holder ahead of Galera’s planned merger with Obsidian Therapeutics.
Investor Intent
Hyare agreed to support Galera’s pending combination with Obsidian Therapeutics. Under a Stockholder Support Agreement signed on April 14, 2026, he committed to “vote all of [his] eligible shares” in favor of approving the mergers and the related actions, and “against any proposal made in opposition to, or in competition with” the deal.
Beyond that commitment, Hyare does not outline specific plans to push corporate changes. He notes he may buy more shares or sell some of his holdings in the future as he evaluates Galera’s business and the market.
Investor's Background
Parvinder Singh Hyare is an American investor and the Chief Executive Officer of Valorum Biologic, Inc. He focuses on healthcare and biotechnology ventures, aligning capital with drug development and clinical-stage assets. Hyare brings operating experience from the sector to his investing decisions.
Original SEC Filing: Galera Therapeutics, Inc. [ GRTX ] - SCHEDULE 13D - Jun. 11, 2026